Miglitol, a new α-glucosidase inhibitor

Bibliography

• DCCT RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• TURNER RC, CULL C, HOLMAN RR: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomised, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann. Intern. Med. (1996) 124:136–145.
   PubMed Web of Science ®Google Scholar
• MIRANDA PM, HORWITZ DL: High fiber diets in the treatment of diabetes mellitus. Ann. Intern. Med. (1978) 88:482–486.
   PubMed Web of Science ®Google Scholar
• JENKINS DJA, WOLEVER TMS, TAYLOR RM, REYNOLDS P NINEHAM R, HOCKADAY TDR: Diabetic glucose control, lipid and trace elements on long term guar. Br. Merl. J. (1980) 280:1353–1354.
   Google Scholar
• AHR H-J, BOBERG M, BRENDEL E, KRAUSE HP, STEINKE W: Pharmacokinetics of miglitol. Arzneim-Forschung/Drug Res. (1997) 47:734–745.
   PubMedGoogle Scholar
• ••Extensive review of the pharmocokinetics of miglitol
   Google Scholar
• LEMBCKE B, FOLSCH VR, CREUTZFELDT W: Effect of 1-deoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro. Digestion (1985) 31:120–127.
   PubMed Web of Science ®Google Scholar
• •Interesting study showing difference of affinities of miglitol for digestive enzymes.
   Google Scholar
• DEBOUNO JF, MICHAELIS IV OE, TULP OL: The effects of the intestinal glucosidase inhibitor Bay M 1099 (Miglitol) on glycemic status of obese rats. Nutr. Res. (1989) 9:1041–1042.
   Google Scholar
• DEBOUNO JF, MICHAELIS IV OE, TULP OL: The effects of the intestinal glucosidase inhibitor Bay M 1099 (Miglitol) on glycemic status of obese rats. Gen. Pharmacol. (1993) 24:509–515.
   PubMedGoogle Scholar
• TULP OL, SZEPESI B, MICHAELIS IV OE, DEBOUNO JF: The effects of low-dose Bay-m 1099 (Miglitol) on serum lipids and liver enzyme activity of obese and obese-diabetic corpulent rats. Comp. Biochem. Physiol. (1991) 99C:241–246.
   Google Scholar
• MADAR Z: The effect of acarbose and miglitol (Bay-M-1099) on postprandial glucose levels following ingestion of various sources of starch by non-diabetic rats. J. Nutr. (1989) 119:2023–2029.
   PubMed Web of Science ®Google Scholar
• MADAR Z, HAZAN A: Effect of miglitol and acarbose on starch digestion, daily plasma profiles and cataract formation. J. Basic Chem. Physiol. Pharmacol. (1993) 4:69–81.
   Google Scholar
• •Compares the effects of acarbose and miglitol on cataract formation in sand rats.
   Google Scholar
• TORMO MA, ROPERO MF, NIETO M, MARTINEZ IM, CAMPILLO JE: In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin dependent diabetic rats. Can. Physiol. Pharmacol (1996) 74:1196–1203.
   PubMedGoogle Scholar
• LUDOLPH D, GROSS V, KATZ NR, GIFFMORN K, KREISELW, HEINRICH PC, GEROK W: Effect of the a-glucosidase inhibitor N-hydroethyl-l-desoxynojirimycin Bay m 1099 on the biosynthesis of liver secretory glycopro-teins. Biochem. Pharmacol (1989) 38:2479–2486.
   PubMedGoogle Scholar
• BOLLEN M, VANDEBROECK A, STALMANS W: 1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase A. Biochem. Pharmacol. (1988) 37:905–909.
   PubMed Web of Science ®Google Scholar
• BOLLEN M, STALMANS W: The antiglycogenolytic activity of 1-deoxynojirimycin results from a specific inhibition of the a-1.6-glucosidase activity of the debranching enzyme. Eur. J. Biochem. (1989) 181:775–780.
   PubMedGoogle Scholar
• SALEHI A, LUNDQUIST T: Ca2+ deficiency, selective aglucoside hydrolase inhibition and insulin secretion. Am. J. Physiol. (1993) 265:E1–E9.
   Google Scholar
• REUSER AJJ, WISSELAAR HA: An evaluation of thepotential side-effects of a glucosidase inhibitors used for the management of diabetes mellitus. Eur. J. Clin. Invest. (1995) 24 (Suppl. 3):19–24.
   Google Scholar
• •Assessment of the real risk of long-term use of miglitol.
   Google Scholar
• WISSELAAR HA, VAN DONGEN JM, REUSER AJJ: Effects ofN-hydroxyethy1-1-deoxynojirimycin (Bay m 1099) on the activity of neutral- and a-glucosidases in human fibroblasts and HepF2 cells. Clin. Chim. Acta (1989) 182:41–52.
   PubMedGoogle Scholar
• KINGMA PJ, MENHEERE PPCA, SELS JP, NIEUWEN-HUIJZEN KRUSEMAN AC: a Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care (1992) 15:478–483.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates that for the day to day use of miglitol a dietary advice concerning the dietary starch content is not necessary.
   Google Scholar
• JOUBERT PH, FOUKARIDIS GN, BOLPAPE ML: Miglitol may have a blood glucose lowering effect unrelated to inhibitory alpha-glucosidase. Eur. Clin. Pharmacol (1987) 31:723–724.
   Google Scholar
• JOUBERT PH, VENTER HL, FOUKARIDIS GN: The effect ofmiglitol and acarbose after oral glucose load: a novel hypoglycaemic mechanism? Br. J. Clin. Pharmacol. (1990) 30:391–396.
   Google Scholar
• SELS JPJE, NAUTA JJP, MENHEERE PPCA, WOLFFEN-BUTTEL BHR, NIEUWENHUIJZEN KRUSEMAN AC: Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers. Br. J. Clin. Pharmacol. (1996) 42:503–506.
   PubMedGoogle Scholar
• •Placebo-controlled study demonstrating that there are no extra-intestinal effects of miglitol.
   Google Scholar
• VENTER HL, MUNTINGH G, ANNESLEY GV: Clinical trial to investigate the existence of a systemic effect of miglitol (single dose of 25 mg, 50 mg, 100 mg and 200 mg) by observing response to oral glucose load: concentration-effect and dose-effect relationship. Bayer AG Report. no R 6340.
   Google Scholar
• •Extensive study using an important number of patients and different doses of miglitol. Systemic effects are not present.
   Google Scholar
• HILLEBRAND I, BOEHME K, GRAEFE KH WEHLING K: The effect of new a-glucosidase inhibitors (Bay m 1099 and Bay o 1248) on meal-stimulated increases in glucose and insulin levels in man. KIM. Wochenschr. (1986) 64:393–396.
   PubMedGoogle Scholar
• LEMBCKE B, FOLSCH UR, GATZEMEIER W, EBERT R, SIEGEL E, CREUTZFELDT W: Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the a-glucosidase inhibitor miglitol (Bay m 1099) in man. Pharmacology (1991) 43:318–328.
   PubMed Web of Science ®Google Scholar
• HEINZ G, KOMJATI M, KORN A, WALDHAUSL W: Reduction of postprandial blood glucose by the a-glucosidase inhibitor miglitol (Bay m 1099) in Type II diabetes. Eur. J. Clin. Pharmacol (1989) 37:33–36.
   PubMedGoogle Scholar
• SCHNACK CH, ROGGLA G, LUGER A, SCHERNTHANER G:Effects of the a-glucosidase inhibitor 1 desoxyno-jirimycin (Bay M 1099) on postprandial blood glucose, serum insulin and C-peptide levels in Type II diabetic patients. Eur. j Clin. Pharmacol. (1986) 30:417–419.
   PubMed Web of Science ®Google Scholar
• REQUEJO F, UTTENTHAL LO, BLOOM SR: Effects of a-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses. Diabetic Med. (1990) 7:515–520.
   PubMedGoogle Scholar
• KATSILAMBROS N, PHILIPPIDES PH, TOSKAS A et al: A double-blind study on the efficacy and tolerance of a new a-glucosidase inhibitor in type-2 diabetics. Arzneim. Forsch./Drug Res. (1986) 36:1136–1138.
   PubMedGoogle Scholar
• ARENDS J, WILLMS BHL: Smoothing effect of a new a-glucosidase inhibitor Bay m 1099 on blood glucose profiles on sulphonylurea-treated Type II diabetic patients. Horm. Metab. Res. (1986) 18:761–764.
   PubMedGoogle Scholar
• WILLMS B, KCJBKE AHRENS K, ARENDS J: Resorptions-verzögerung de Kohlenhydrate in der Therapie de Typ-II-Diabetes: Vergleich zwisschen diätetischer (Mush) und pharmacologischer (a-Glucosidasehe-mmung) Beeinflussing. Schweiz. Med. Wschr. (1991) 121:1379–1382.
   PubMedGoogle Scholar
• JOUBERT PH, BAM WJ, MANYANE N: Effect of an alpha-glucosidase inhibitor (Bay m 1099) on postprandial blood glucose and insulin in Type II diabetics. Eur. J. Pharmacol. (1986) 30:253–255.
   Google Scholar
• SELS JPJE, KINGMA PJ, WOLFFENBUTTEL BHR, MENHEERE PPCA, BRANOLTE JH, NIEUWENHUIJZEN KRUSEMAN AC: Effect of miglitol (Bay m 1099) on fasting blood glucose in Type 2 diabetes mellitus. Neth. J. Med. (1994) 44:198–201.
   PubMedGoogle Scholar
• •This study demonstrates that miglitol cannot prevent the noctural rise of blood glucose in Type 2 diabetes patients.
   Google Scholar
• RENARD E, PARER-RICHARD C, RICHARD J-L, JUREIDINI S, ORSETTI A, MIROUZE J: Effect of miglitol (Bay m 1099) a new a-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms. Diab. Metabol (1991) 17:355–362.
   PubMedGoogle Scholar
• LEMBCKE B, DIEDERICH M, FOLSCH UR, CREUTZFELDT W: Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol. Digestion (1990) 47:47–55.
   PubMed Web of Science ®Google Scholar
• JOHNSTON PS, FEIG PU, CONIFF RF, KROL A, DAVIDSON JA, HAFFNER SM: Long-term titrated dose a-glucosidase inhibition in non-insulin-requiring hispanic NIDDM patients. Diabetes Care (1998) 21:409–415.
   PubMed Web of Science ®Google Scholar
• JOHNSTON PS, FEIG PU, CONIFF RF, KROL A, KELLEY DE, MOORADIAN AD: Chronic treatment of african-american Type 2 diabetic patients with a-glucosidase inhibition. Diabetes Care (1998) 21:416–422.
   PubMed Web of Science ®Google Scholar
• ••Placebo-controlled study in a population with highprevalence of Type 2 diabetes.
   Google Scholar
• SEGAL P, FEIG PU, SCHERTNTHALER G etal: The efficacy and safety of miglitol therapy compared with gliben-clamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care (1997) 20:687–691.
   PubMed Web of Science ®Google Scholar
• JONHNSTON PS, LEBOVITZ HE, CONIFF RF, SIMONSONDC, RASKIN P, MUNERA C: Advantages of a-glucosidase inhibition as monotherapy in elderly Type 2 diabetic patients. J. Clin. Endocrinol. Metab. (1998) 83:1515–1522.
   PubMedGoogle Scholar
• •This study demonstrated the usefulness of miglitol in this particular population
   Google Scholar
• JOHNSTON PS, CONIFF RF, HOOGWERF BJ, SANTIAGOJV, XAVIER PI-SUNYER, KROL A: Effects of the carbohy-drase inhibitor miglitol in sulphonylurea-treated NIDDM patients. Diabetes Care (1994) 17:20–29.
   PubMed Web of Science ®Google Scholar
• MITRAKOU A, TOUNTAS N, RAPTIS AE, BAUER RJ, SCHULZ H, RAPTIS SA: Long-term effectiveness of a new a-glucosidase inhibitor (Bay m1099-Miglitol) in insulin-treated Type 2 diabetes mellitus. Diabetic Med. (1998) 15:657–660.
   PubMed Web of Science ®Google Scholar
• PAGANO G, MARENA S, CORGIAT-MANSIN L et al: Comparison of miglitol and glibenclamide in diet-treated Type 2 diabetic patients. Diab. Metabol (1995) 21:162–167.
   PubMed Web of Science ®Google Scholar
• •This study demonstarted that miglitol was not superior to a frequently-used sulphonylurea compound. Glibenclamide gave a greater reduction of HbAl c.
   Google Scholar
• SCHNACK C, PRAGER RJF, WINKLER J, KLAUSER RM, SCHNEIDER BG, SCHERNTHANER G: Effects of 8-wk a-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled Type II diabetic patients. Diabetes Care (1989) 12:537–543.
   PubMedGoogle Scholar
• JOHNSON AB, TAYLOR R: Does suppression of postprandial blood glucose excursions by the a-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated Type II diabetic patients? Diabetes Care (1996) 19:559–563.
   PubMedGoogle Scholar
• •Improvement of glycaemic control could increase insulin sensitivity. Smoothing postprandial blood glucose levels by miglitol could have this consequence. This study could not demonstrate a change in insulin sensitivity, probably caused by the limited reduction of blood glucose levels by miglitol.
   Google Scholar
• MAISLOS M, VAN GAAL L, SEGAL P: Miglitol in combina-tion with metformin improves glucaemic control in Type 2 diabetics. Diabetologia (1999) 45:A223.
   Google Scholar
• STANDL E, SCHERNTHANER G, RYBKA J, HANEFELD M: Improved glycaemic control with miglitol in Type 2 diabetics insufficiently controlled on oral hypigly-caemics. Diabetologia (1999) 45:A223
   Google Scholar
• RYBKA J, GOKE B, SISSMANN J: European comparative study of 2 alpha-glucosidase inhibitors, miglitol and acarbose. Diabetes (1999) 48 (Suppl. 1):A101.
   Google Scholar
• WING J, KALK WJ, BERZIN M et al.: The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics. S. Afric. Med. J. (1990) 77:286–288.
   PubMedGoogle Scholar
• HILLMAN RJ, SCOTT M, GRAY RS: Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes. Diabetes Res. (1989) 10:81–84.
   PubMedGoogle Scholar
• DIMITRIADES G, HATZIAGELLAKI E, ALEXOPOULOS E et al. Effects of a-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in Exp. Opin. Pharmacother. (1999) 1(1) patients with Type I diabetes mellitus. Diabetes Care (1991) 14:393–398.
   PubMedGoogle Scholar